Siltuximab CNTO-328|cas:541502-14-1|西域试剂

Siltuximab CNTO-328,99.90%

产品编号：Bellancom-P9956| CAS NO：541502-14-1

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P9956	￥1900.00	杭州北京（现货）
Bellancom-P9956	￥5700.00	杭州北京（现货）
Bellancom-P9956	￥9120.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Siltuximab CNTO-328

产品介绍

Siltuximab 是一种 anti-IL-6 (interleukin-6) 单克隆抗体，具有抗肿瘤活性。Siltuximab 可用于多中心性巨大淋巴结增生症 (MCD) 和 COVID-19 的研究。

生物活性

Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research.

体外研究

体内研究

Siltuximab (intraperitoneal injection; 10 mg/kg; 3 times per week) inhibits the growth of lung cancer cells in xenograft mouse model.
Siltuximab (intraperitoneal injection; 20 mg/kg; twice per week; 6 w) inhibits the growth of MCF-7 tumor in xenograft model^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female CD-1 nu/nu mice injected with H1650 (adenocarcinoma), H322 (adenocarcinoma), or H157 (squamous) cells
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; 10 mg/kg; 3 times per week
Result:	Repressed PY-STAT3 levels stimulated by IL-6 in H322 cells. Repressed PY-STAT3 levels in H1650 cells. Inhibited the growth of tumors with H322 and CAF cells. Inhibited the growth of tumors with H1650 and CAF cells.

Animal Model:	Female NOD-SCID mice with MCF-7 tumor^[4]
Dosage:	20 mg/kg
Administration:	Intraperitoneal injection; 20 mg/kg; twice per week; 6 weeks
Result:	Blocked MCF-7 engraftment, induced regressions in 90% of tumors.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female CD-1 nu/nu mice injected with H1650 (adenocarcinoma), H322 (adenocarcinoma), or H157 (squamous) cells
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; 10 mg/kg; 3 times per week
Result:	Repressed PY-STAT3 levels stimulated by IL-6 in H322 cells. Repressed PY-STAT3 levels in H1650 cells. Inhibited the growth of tumors with H322 and CAF cells. Inhibited the growth of tumors with H1650 and CAF cells.

Animal Model:	Female NOD-SCID mice with MCF-7 tumor^[4]
Dosage:	20 mg/kg
Administration:	Intraperitoneal injection; 20 mg/kg; twice per week; 6 weeks
Result:	Blocked MCF-7 engraftment, induced regressions in 90% of tumors.